PTHS — Pelthos Therapeutics Inc.

Pelthos Therapeutics Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Product Revenue: $7.1 million for Q3 2025, attributed to the launch of ZELSUVMI.
• Operating Loss: $15.4 million; GAAP net loss of $16.2 million ($5.30 per share).
• As-Converted Loss: $1.83 per share when accounting for Series A and C shares.
• Cash Position: $14.2 million in cash and $8 million in accounts receivable as of September 30, 2025.
• Gross to Net (GTN): 25.3% for Q3, expected to rise to mid- to high 30% range by Q1 2026.
• Sales Force: 50 representatives currently, with plans to expand by 14 to cover additional metropolitan areas.

2. Strategic Updates and Business Highlights

• Product Launch: ZELSUVMI, a topical treatment for molluscum contagiosum, launched in mid-July 2025 and is the first FDA-approved at-home therapy for this condition.
• Acquisition of Xepi: Recently acquired for $4.2 million, Xepi is a topical treatment for impetigo, complementing ZELSUVMI and leveraging existing sales infrastructure.
• Investor Confidence: Secured $50 million PIPE financing and an additional $18 million in convertible notes to support product launches and acquisitions.
• Market Position: ZELSUVMI is positioned as a first-line treatment, with positive feedback from healthcare providers and parents.

3. Forward Guidance and Outlook

• Cash Flow Breakeven: Expected to achieve cash flow breakeven before the end of 2026, driven by ZELSUVMI's growth.
• Growth Projections: Anticipating significant revenue increase for Q4 2025 compared to Q3, with a projected annual gross revenue run rate of approximately $52 million.
• Peak Revenue Target: Aiming for $175 million in peak revenue by 2028.

4. Bad News, Challenges, or Points of Concern

• Operating Losses: Continued significant operating losses, with a net loss of $16.2 million in Q3.
• Seasonality Risks: Potential softening of prescription growth during holiday periods due to reduced patient visits.
• Dependence on New Patients: As an acute medication, ZELSUVMI relies on new patient visits for prescriptions, which may be impacted by office closures during holidays.
• Market Competition: Although ZELSUVMI is a novel treatment, the competitive landscape for dermatological products remains a concern.

5. Notable Q&A Insights

• Prescriber Engagement: Approximately 60% of unique prescribers have written one prescription, with some prescribing multiple units.
• Impact of Holidays: There is concern that holiday closures may temporarily affect prescription volumes, although the product's acute nature may mitigate this.
• Sales Force Profitability: Current sales representatives are profitable, and the expansion is based on proven market demand.
• Pricing Strategy: The company is considering responsible price increases in the future, particularly since they do not currently have commercial contracts that would limit pricing flexibility.

Overall, Pelthos Therapeutics is navigating a promising launch phase with ZELSUVMI and the acquisition of Xepi, while facing challenges typical of new product introductions in the pharmaceutical space. The company maintains a strong financial position but must manage operational losses and market dynamics as it scales.